Veracyte Inc (VCYT) 8.77 $VCYT
Veracyte Announces Publication of Data Demonstrating Analytical and Clinical Validity of Its Afirma® BRAF Malignancy Classifier
PR Newswire - Thu Feb 05, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of data demonstrating the analytical and clinical validity of Afirma® BRAF, the company's malignancy classifier for identifying BRAF V600E mutation status among thyroid nodule biopsies. The data, which appear in the current issue of Pacific Symposium on Biocomputing, confirm that the Afirma RNA-based classifier detects the BRAF V600E mutation with high diagnostic accuracy.
VCYT: 8.77 (+0.22)
Veracyte to Present at the Leerink Partners 2015 Global Healthcare Conference
PR Newswire - Wed Feb 04, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Leerink Partners 2015 Global Healthcare Conference on Wednesday, February 11, 2015 at 11:30 a.m. ET in New York, NY.
VCYT: 8.77 (+0.22)
5 Stocks Ready for Breakouts: Veracyte, Flextronics and More
at The Street - Fri Jan 30, 5:00AM CST
These stocks look poised to break out and trade higher from current levels.
FLEX: 12.05 (-0.09), EXXI: 4.00 (+0.42), VCYT: 8.77 (+0.22), XGTI: 0.43 (+0.01), RGLS: 16.85 (-0.13)
Veracyte, Inc. Names Dr. Robert S. Epstein to Its Board of Directors
PR Newswire - Mon Jan 12, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointment of Robert S. Epstein, M.D., M.S., to its Board of Directors.
VCYT: 8.77 (+0.22), ILMN: 198.54 (+1.81)
Veracyte to Present at the J.P. Morgan 33rd Annual Healthcare Conference
PR Newswire - Thu Jan 08, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the J.P. Morgan 33rd Annual Healthcare Conference on Thursday, January 15, 2015, at 8:30 a.m. Pacific Time in San Francisco, Calif.
VCYT: 8.77 (+0.22), JPM: 59.67 (+0.10)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 12:21PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NRCIA: 14.60 (-0.24), VCYT: 8.77 (+0.22), ISIS: 63.86 (-0.43), CBST: 101.94 (+0.14), AKAO: 11.11 (-0.27), CLDN: 16.45 (-0.05), PDCE: 49.17 (+0.60), MTEX: 23.89 (+0.69), NRCIB: 35.75 (+1.95)
Veracyte Announces Positive Coverage Policy for Afirma® Gene Expression Classifier from Blue Shield of California
PR Newswire - Tue Dec 02, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced today that Blue Shield of California, one of the nation's largest Blue Cross Blue Shield (BCBS)-affiliated organizations, has issued a positive coverage policy for the company's Afirma Gene Expression Classifier (GEC), effective immediately. Blue Shield of California's decision makes the Afirma GEC available to its approximately 3 million members and brings the total number of covered lives for Veracyte's test to more than 140 million. Additionally, the Hawaii Medical Services Association (HMSA) - also a BCBS-affiliated organization - published a draft policy indicating it intends to cover Veracyte's genomic test for its members beginning in February 2015.
VCYT: 8.77 (+0.22)
Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference
PR Newswire - Mon Nov 24, 6:39AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. ET in New York.
VCYT: 8.77 (+0.22)
Veracyte's (VCYT) CEO Bonnie Anderson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 11:45PM CST
VCYT: 8.77 (+0.22)
Veracyte misses Street 3Q forecasts
Automated Insights - Thu Nov 13, 4:48PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a third-quarter loss of $7.9 million.
VCYT: 8.77 (+0.22)
Veracyte misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:31PM CST
VCYT: 8.77 (+0.22)
Veracyte, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:05PM CST
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the third quarter ended September 30, 2014 and provided an update on business progress. For the third quarter of 2014, revenue was $9.8 million, an increase of 76%, compared to $5.6 million for the third quarter of 2013. Revenue for the nine months ended September 30, 2014 was $26.0 million, compared to $15.0 million for the same period in 2013, an increase of 73%.
VCYT: 8.77 (+0.22)
Veracyte Announces Appointment of John L. Bishop to Its Board of Directors Following the Resignation of Samuel D. Colella
PR Newswire - Wed Nov 12, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced the resignation of Samuel D. Colella from its Board of Directors, effective November 30, 2014. The Veracyte Board accepted his resignation at its November 11, 2014 meeting, during which it also approved the selection of veteran diagnostics executive John L. Bishop to fill the vacancy left by Mr. Colella, effective December 1, 2014. Mr. Bishop will also join the Board's Compensation Committee.
VCYT: 8.77 (+0.22)
Veracyte, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2014 Financial Results on November 13, 2014
PR Newswire - Thu Nov 06, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2014 financial results will be released after close of market on Thursday, November 13, 2014. Following the announcement, Veracyte's management will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
VCYT: 8.77 (+0.22)
Veracyte, Inc. Announces New Data Supporting Clinical Validity of Afirma® Gene Expression Classifier
PR Newswire - Wed Oct 29, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced new data from two studies supporting the use of the company's Afirma Gene Expression Classifier (GEC) to help reduce unnecessary surgeries among patients whose thyroid nodules are indeterminate for cancer following traditional cytopathology review of their fine needle aspiration (FNA) biopsies. The data are being presented at the 84th Annual Meeting of the American Thyroid Association in Coronado, Calif., October 29 - November 2.
VCYT: 8.77 (+0.22)
Veracyte Inc. to Host Investor Day on October 9, 2014
PR Newswire - Thu Oct 02, 6:30AM CDT
Veracyte Inc. (Nasdaq: VCYT) today announced that the company will host a live webcast in conjunction with its Investor Day on Thursday, October 9, 2014 at 12:00 p.m. ET in New York, NY.
VCYT: 8.77 (+0.22)
Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer
PR Newswire - Wed Sep 17, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the promotion of Christopher M. Hall to chief operating officer.
VCYT: 8.77 (+0.22)
Veracyte, Inc. to Acquire Allegro Diagnostics, Accelerating Entry Into Pulmonology Market
PR Newswire - Thu Sep 04, 3:30PM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced an agreement to acquire Allegro Diagnostics Corp. based in Maynard, Mass., for $21.0 million, comprised of $7.8 million in cash and $13.2 million in Veracyte common stock. Allegro is a privately held company focused on developing genomic tests to improve the preoperative diagnosis of lung cancer.
VCYT: 8.77 (+0.22)
Veracyte Announces Publication of Data Demonstrating Analytical and Clinical Validity of Its Afirma® BRAF Malignancy Classifier
PR Newswire - Thu Feb 05, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of data demonstrating the analytical and clinical validity of Afirma® BRAF, the company's malignancy classifier for identifying BRAF V600E mutation status among thyroid nodule biopsies. The data, which appear in the current issue of Pacific Symposium on Biocomputing, confirm that the Afirma RNA-based classifier detects the BRAF V600E mutation with high diagnostic accuracy.
VCYT: 8.77 (+0.22)
Veracyte to Present at the Leerink Partners 2015 Global Healthcare Conference
PR Newswire - Wed Feb 04, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Leerink Partners 2015 Global Healthcare Conference on Wednesday, February 11, 2015 at 11:30 a.m. ET in New York, NY.
VCYT: 8.77 (+0.22)
5 Stocks Ready for Breakouts: Veracyte, Flextronics and More
at The Street - Fri Jan 30, 5:00AM CST
These stocks look poised to break out and trade higher from current levels.
FLEX: 12.05 (-0.09), EXXI: 4.00 (+0.42), VCYT: 8.77 (+0.22), XGTI: 0.43 (+0.01), RGLS: 16.85 (-0.13)
Veracyte, Inc. Names Dr. Robert S. Epstein to Its Board of Directors
PR Newswire - Mon Jan 12, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointment of Robert S. Epstein, M.D., M.S., to its Board of Directors.
VCYT: 8.77 (+0.22), ILMN: 198.54 (+1.81)
Veracyte to Present at the J.P. Morgan 33rd Annual Healthcare Conference
PR Newswire - Thu Jan 08, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the J.P. Morgan 33rd Annual Healthcare Conference on Thursday, January 15, 2015, at 8:30 a.m. Pacific Time in San Francisco, Calif.
VCYT: 8.77 (+0.22), JPM: 59.67 (+0.10)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 12:21PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NRCIA: 14.60 (-0.24), VCYT: 8.77 (+0.22), ISIS: 63.86 (-0.43), CBST: 101.94 (+0.14), AKAO: 11.11 (-0.27), CLDN: 16.45 (-0.05), PDCE: 49.17 (+0.60), MTEX: 23.89 (+0.69), NRCIB: 35.75 (+1.95)
Veracyte Announces Positive Coverage Policy for Afirma® Gene Expression Classifier from Blue Shield of California
PR Newswire - Tue Dec 02, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced today that Blue Shield of California, one of the nation's largest Blue Cross Blue Shield (BCBS)-affiliated organizations, has issued a positive coverage policy for the company's Afirma Gene Expression Classifier (GEC), effective immediately. Blue Shield of California's decision makes the Afirma GEC available to its approximately 3 million members and brings the total number of covered lives for Veracyte's test to more than 140 million. Additionally, the Hawaii Medical Services Association (HMSA) - also a BCBS-affiliated organization - published a draft policy indicating it intends to cover Veracyte's genomic test for its members beginning in February 2015.
VCYT: 8.77 (+0.22)
Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference
PR Newswire - Mon Nov 24, 6:39AM CST
Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. ET in New York.
VCYT: 8.77 (+0.22)
Veracyte's (VCYT) CEO Bonnie Anderson on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 11:45PM CST
VCYT: 8.77 (+0.22)
Veracyte misses Street 3Q forecasts
Automated Insights - Thu Nov 13, 4:48PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Veracyte Inc. (VCYT) on Thursday reported a third-quarter loss of $7.9 million.
VCYT: 8.77 (+0.22)
Veracyte misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:31PM CST
VCYT: 8.77 (+0.22)
Veracyte, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Nov 13, 3:05PM CST
Veracyte, Inc. (Nasdaq: VCYT) today reported financial results for the third quarter ended September 30, 2014 and provided an update on business progress. For the third quarter of 2014, revenue was $9.8 million, an increase of 76%, compared to $5.6 million for the third quarter of 2013. Revenue for the nine months ended September 30, 2014 was $26.0 million, compared to $15.0 million for the same period in 2013, an increase of 73%.
VCYT: 8.77 (+0.22)
Veracyte Announces Appointment of John L. Bishop to Its Board of Directors Following the Resignation of Samuel D. Colella
PR Newswire - Wed Nov 12, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced the resignation of Samuel D. Colella from its Board of Directors, effective November 30, 2014. The Veracyte Board accepted his resignation at its November 11, 2014 meeting, during which it also approved the selection of veteran diagnostics executive John L. Bishop to fill the vacancy left by Mr. Colella, effective December 1, 2014. Mr. Bishop will also join the Board's Compensation Committee.
VCYT: 8.77 (+0.22)
Veracyte, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2014 Financial Results on November 13, 2014
PR Newswire - Thu Nov 06, 6:30AM CST
Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2014 financial results will be released after close of market on Thursday, November 13, 2014. Following the announcement, Veracyte's management will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
VCYT: 8.77 (+0.22)
Veracyte, Inc. Announces New Data Supporting Clinical Validity of Afirma® Gene Expression Classifier
PR Newswire - Wed Oct 29, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced new data from two studies supporting the use of the company's Afirma Gene Expression Classifier (GEC) to help reduce unnecessary surgeries among patients whose thyroid nodules are indeterminate for cancer following traditional cytopathology review of their fine needle aspiration (FNA) biopsies. The data are being presented at the 84th Annual Meeting of the American Thyroid Association in Coronado, Calif., October 29 - November 2.
VCYT: 8.77 (+0.22)
Veracyte Inc. to Host Investor Day on October 9, 2014
PR Newswire - Thu Oct 02, 6:30AM CDT
Veracyte Inc. (Nasdaq: VCYT) today announced that the company will host a live webcast in conjunction with its Investor Day on Thursday, October 9, 2014 at 12:00 p.m. ET in New York, NY.
VCYT: 8.77 (+0.22)
Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer
PR Newswire - Wed Sep 17, 6:30AM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the promotion of Christopher M. Hall to chief operating officer.
VCYT: 8.77 (+0.22)
Veracyte, Inc. to Acquire Allegro Diagnostics, Accelerating Entry Into Pulmonology Market
PR Newswire - Thu Sep 04, 3:30PM CDT
Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced an agreement to acquire Allegro Diagnostics Corp. based in Maynard, Mass., for $21.0 million, comprised of $7.8 million in cash and $13.2 million in Veracyte common stock. Allegro is a privately held company focused on developing genomic tests to improve the preoperative diagnosis of lung cancer.
VCYT: 8.77 (+0.22)
